Advances in technology to assess immunologic risk in solid organ transplant offer an opportunity to optimize the approach to pediatric deceased donor kidney transplant in the setting of a new allocation system in the United States.
INTRODUCTION
The demand for kidney transplantation continues to outstrip the supply for available kidneys worldwide. Since 1999, living-related donation in pediatric kidney transplant programs has decreased from 45 to 30% [1] . Pediatric kidney transplant recipient outcomes are linked to age at transplant, degree of alloimmune sensitization, and living versus deceased kidney donors [2, 3] . Central to these factors are the immunological risk of the donated organ to the recipient. Pretransplant histocompatibility screening aids in the identification of highrisk kidney transplant recipients. Enhancement of histocompatibility tools may improve not only first kidney transplant allograft outcomes, but also decrease a lifetime of immunologic risk in future kidney transplants. This review of current histocompatibility techniques aims to guide pediatric transplant clinicians to match the best quality organ to pediatric kidney transplant candidates.
IMMUNOBIOLOGY IN KIDNEY TRANSPLANT
Human leukocyte antigen (HLA) antigen proteins on cell surfaces are important to differentiation of self from nonself proteins [4 && ]. Major histocompatibility complex (MHC), a collection of more than 200 genes on chromosome 6p, encodes HLA proteins. The two groups of MHC genes relevant to transplantation are class I and class II. Class I MHC genes (HLA-A, HLA-B, and HLA-C) produce class I MHC molecules, which have two polypeptide chains: a polymorphic a chain and an invariable b 2 microglobulin chain. Class I HLA variability results from the peptide-binding region, the a 1 and a 2 domains. Class I HLA proteins are expressed on the surface of nearly every nucleated cell. There are nine primary MHC class II genes: HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5. These class II molecules also consist of two chains, a and b, with the class HLA variability in the peptidebinding regions of the a 1 and b 1 domains. Class II HLA proteins are expressed on antigen presenting cells, such as macrophages, B cells, and dendritic cells. Each HLA protein is expressed from two alleles, with a high degree of HLA genetic polymorphism. One exception is HLA-DRA, which is invariant in the peptide-binding regions.
The adaptive immune response develops immunologic memory and antigen specificity by way of T cell recognition of alloantigens [5, 6] . Acute cellular and humoral rejections in kidney transplant occur as a result of recognition of donor antigens leading to activation of T and B cells, creation of donorspecific antibodies (DSAs), and the antibody-mediated activation of the complement cascade.
The immunologic risk of children as compared to adults has been considered to be lower due to a more naïve immune system (lower T-cell activity and lower anti-HLA antibodies prior to transplantation) [3] . The immunological stakes are higher for a child who will likely need a second and third kidney transplant later in life.
HISTOCOMPATIBILITY METHODS

Complement-dependent lymphocytotoxicity crossmatch
Preformed antibody in the transplant recipient is screened by use of the qualitative complementdependent lymphocytotoxicity (CDC) crossmatch, in which recipient serum is incubated with potential donor B and T cells that express known HLA class I and II antigens, followed by addition of complement and analysis of cell lysis (Table 1) . Panel-reactive antibodies (PRAs) are calculated by the percentage of panel cells that are killed by recipient serum.
A reduction in the false negative crossmatch rate is achieved with the antihuman-immunoglobulinenhanced CDC (AHG-CDC) assay [7] [8] [9] . AHG is added prior to complement to crosslink a larger number of molecules, enhancing complement-mediated cytotoxic cell death. These CDC methods are qualitative, and their interpretation is subjective.
Flow cytometry crossmatch
Fluorescent-labeled reagents directed against anti-HLA antibodies as well as T and B-cell-specific cell surface proteins (CD3 for T cells, CD19 for B cells) are added to cell samples to perform the flow cytometry crossmatch (FCXM) and detect antibody bound to individual T and B cells. This whole-cell-based technique offers definitive antibody and class identification. The addition of pronase (an agent that digests Fc receptors and other cell surface proteins) aids in decreasing nonspecific background binding of the Fc receptors and autoantibodies, improving FCXM sensitivity and specificity [10] .
Solid-phase assays
Solid-phase assays (SPA) detect antibody either through purified HLA antigens affixed to microparticle beads that are analyzed by flow cytometry or by ELISA [11] [12] [13] [14] [15] . Candidate serum is added to the SPA, anti-HLA antibodies bind to the antigens, and fluorescent antihuman globulins are added and illuminate when bound to anti-HLA antibodies, measured in mean fluorescence intensity (MFI). The addition of SPA improved the validity of clinically relevant positive crossmatch results by increasing specificity and controlling for non-HLA antibodies and falsepositive results. The HLA antigen purification process itself can destabilize the antigen, changing their confirmation and leading to cryptic (previously hidden) antigen expression [16] . A DSA specific to a cryptic antigen may not be clinically relevant, yet a positive result may prevent a recipient from receiving an acceptable donor kidney. Due to the variable antigen density of microparticle beads, there can be interassay and intraassay variability between SPA, though guidelines now have been suggested for SPA techniques both pretransplant and posttransplant [17] .
Complement-fixing SPA technology determines the ability of DSA to bind complement, potentially offering additional specificity to detecting clinically relevant DSA. The Luminex (Life Technologies, Thermo Fisher Scientific Corp, Carlsbad, California, USA) single-antigen bead (SAB) platform utilizes C1q binding by combining HLA-coated SAB, patient serum, and an exogenous source of
KEY POINTS
Degree of HLA matching affects long-term outcomes for pediatric recipients in both first and future kidney transplants.
Advances in histocompatibility tools increase degree of matching between donor and recipients.
Decreasing immunologic risk through eplet matching may provide better utilization of donor kidneys to the best HLA-matched transplant recipients.
Posttransplant monitoring of dnDSA plays an important role in detecting acute rejection and may be used to identify those at risk for worse long-term allograft outcomes.
C1q. Fluorescent anti-C1q antibody is added and illuminates complement-fixing antibodies, independent of the strength of the IgG MFI. The C1q-binding DSA has been correlated to rejection and graft failure in kidney transplant recipients, though there is again variability in the availability of C1q assays and performance [18] [19] [20] .
Epitope mapping
Epitopes, the part of the HLA antigen that antibody recognizes, are characterized by short sequences of amino acid residues termed eplets. Duquesnoy and Askar developed the HLAMatchmaker, a molecularly based algorithm that determines which eplets are different between donor and recipient [21, 22] . Epitopes have also been identified through analysis of SAB reactivity of mAbs or alloantibodies adsorbed and then eluted on recombinant single antigen cell lines [23] . Electrostatic potentials of HLA epitopes can also be calculated through three-dimensional structural modeling and correlated with well characterized HLA binding assays, suggesting a role for this computational method for predicting HLA antigenicity [24] . These advances in epitope mapping may improve probability of transplantation and longterm outcomes.
PRETRANSPLANT HISTOCOMPATIBILITY LISTING FACTORS
Unacceptable antigens and calculating calculated panel-reactive antibody
Candidates undergo HLA typing as well as evaluation for preexisting anti-HLA antibodies. Patients with well-defined anti-HLA antibodies with confirmation by SPA are listed as unacceptable antigens. As SPA has great sensitivity, some transplant centers may use multiple dilutions of the patient's sera to determine if fluorescence shift is proportional to the titer of the antibody. A transplant center utilizes SPA data to determine individual cutoff levels of MFI to determine unacceptable antigens to be avoided to prevent hyperacute, accelerated antibody-mediated rejections or chronic allograft nephropathy [25] . The breadth of sensitization is measured by calculated PRAs (cPRA) in the United States and similar statistics in Europe and the United Kingdom. The calculation is based on the frequency of donors with unacceptable antigens and is based on regional differences in HLA antigen distributions.
Preliminary and final crossmatch
Serum samples from potential kidney transplant recipients who are actively waitlisted are routinely screened, and a preliminary crossmatch is made against donor cells using this serum. 'Virtual' crossmatch is performed in some centers when the candidate's unacceptable antigens have been entered into the UNOS database (UNET) system. If the preliminary crossmatch is negative, then a final crossmatch is made with either AHG-CDC or FCXM using recent (within the last month) or fresh sera.
Pediatric kidney allocation system
With the initiation of the current Organ Procurement and Transplantation Network kidney allocation system in 2014, an emphasis was placed on promoting longevity matching between donor and recipient to utilize the maximum amount of graft years through an estimated posttransplant survival score [26] . Pediatric candidates will continue to have high-quality kidneys allocated to children less than 18 years of age, from donors with a kidney donor profile index of less than 35%. Priority on a sliding scale continues for highly sensitized candidates based on cPRA score starting at a cPRA more than 20%, with the largest gains for priority for cPRA more than 90%. Therefore, clinical decision making for accepting kidney donors should continue to emphasize that pediatric transplant recipients receive the best quality kidney donors to enhance both patient and allograft survival.
IMMUNE MONITORING AND PEDIATRIC KIDNEY POSTTRANSPLANT OUTCOMES
Human leukocyte antigen mismatch
HLA matching is a well-known predictor of renal allograft survival, though our current allocation system does not account for degree of HLA mismatch [27] [28] [29] . With a limited organ supply, paucity of living donors, and a desire to decrease waiting time on dialysis, pediatric recipients are transplanted with a high degree of mismatching. Foster et al. [30 & ] demonstrated that in a United States Renal Data System cohort of 8433 pediatric patients from 1988 to 2000, in patients less than 21 years of age at first transplant, patients with 0-1 mismatch displayed 15% more time with a functioning graft than patients having 2-3 mismatch with their first allografts, who likewise had 12% more time than those with 4-6 mismatch allografts. In a subset of 2498 patients that were subsequently listed for a second transplant, 0-1 mismatch first transplant recipients were 26% more likely to be successfully transplanted with a second transplant.
De novo donor-specific antibody
The development of de novo DSA (dnDSA) has been associated with higher degree of HLA mismatch and poorer allograft outcomes [31] [32] [33] . dnDSA was detected in 6% of patients in a prospective study that monitored HLA antibody and protocol biopsies in a US pediatric cohort (n ¼ 124) on steroid-based (n ¼ 60) and steroid-free (n ¼ 64) immunosuppression (ISS) protocols [2] . The development of dnDSA was associated with overall worse graft function at 6, 12, and 24 months after transplant (P ¼ 0.02), higher risk for acute rejection (P ¼ 0.02), and chronic allograft failure (P ¼ 0.02) in this cohort. At 2 years posttransplant, this cohort had 100% patient survival, but five patients had lost their allografts, each associated with both nonadherence to ISS and greater than three HLA mismatches, with no difference in steroid-based or steroid-free ISS. In an Italian cohort of 114 pediatric transplant recipients, 39 patients developed dnDSA, 15 of which developed early dnDSA, within one year of transplant [34] . Regardless of timing of appearance, dnDSA was associated with late antibody-mediated rejection in 47% of early group and 58% of the late group, and allograft loss occurred in early and late dnDSA groups (20 and 17%, respectively) in a median follow-up time of 6.7 years.
Although class I and II HLA mismatch of HLACw, HLA-DR, HLA-DP, and HLA-DQ are not considered in the organ allocation system, they have been associated with development of dnDSA, acute rejection, and worse allograft outcomes [35, 36] . In a UK pediatric cohort (n ¼ 215) with prospective monitoring of HLA antibodies, 35% of patients developed dnDSA at a median of 0.25 years posttransplant, with a high prevalence of class II dnDSA (70%), of which 45% were anti-HLA-DQ [37] . In 47% of patients who had earlier (<4 months posttransplant) dnDSA detection and lower MFI at detection (<3500 MFI), dnDSA resolved. Patients who were dnDSA positive had a more rapid decline in kidney function, with 50% reduction of estimated glomerular filtration rate from posttransplant nadir at 5.3 versus 6.1 years (P ¼ 0.02). Of 11 916 pediatric kidney transplant recipients from the US Scientific Registry of Transplant Recipients database from 1990 to 2008, 2704 were relisted following first kidney allograft failure, of which 15.5% were retransplanted, and 7.2% remained on the wait list [38] . Mean PRA and waiting time increased significantly with degree of HLA-DR mismatch with first and second kidney transplant in this cohort. HLA-DR mismatch greater than two was associated with worse outcomes at 5 years following second kidney transplant, as compared with 0-1 mismatch.
An Italian pediatric cohort of 48 nonsensitized kidney transplant recipients with 65 for-cause biopsy data also demonstrated that high serum dnDSA (>10 000 MFI) was associated with intragraft dnDSA detected from eluent from graft pellets by SAB [39] . Intragraft dnDSA, termed graft homing, has been associated with worse allograft outcomes [40] .
C1qþ dnDSA has been associated with a higher risk of kidney transplant loss than C1qÀ dnDSA [18, 20, 41] . It has been demonstrated that C1qþ dnDSA correlates strongly with high HLA antibody MFI. In a French study of 346 adult nonsensitized kidney transplant recipients evaluated at 2 and 5 years posttransplant, 3.5 and 2.5% had C1qþ dnDSA [42] . Compared with patients without dnDSA, presence of C1q-nonbinding dnDSA and C1q-binding dnDSA at 2 and 5 years post-transplant was associated with worse 10-year allograft survival (P < 0.001 and P ¼ 0.002, respectively). To better understand the role of C1q and complement fixation in predicting allograft outcomes, C3d-binding and combined C1q and C3d SAB assays were performed in 39 Italian pediatric kidney transplant recipients who developed dnDSA [43 && ]. Patients with persistent noncomplement-binding dnDSA acquired C1q binding ability, and likewise persistent C1q-binding dnDSA acquired C3d binding ability over time. C3d-binding was associated with lower 10-year graft survival probability compared with patients without dnDSAs, those with C1qþ/C3d À binding dnDSA, or those with noncomplement-binding dnDSAs. C3d-binding dnDSA was also correlated with antibody mediated rejection development. These data suggest that there is progressive acquisition of dnDSA complement-binding ability over time, as detection of C3 fragments is an indicator of ongoing complementactivation. This also supports a paradigm in which two separate processes mediate chronic antibodymediated graft injury initiated by DSA deposition: one that is mediated through antibody-dependent cell cytotoxicity and the other by the complement classic pathway. Wiebe et al. [44] also performed C1q-binding SAB assays in 70 Canadian kidney transplant recipients, and found that C1qþ dnDSA was associated with allograft loss, as was high dnDSA titer, but was not independently associated with outcomes when taking into account clinical phenotype (renal biopsy) and an admission of nonadherence. These data taken together may suggest that C1qþ dnDSA status is a reflection of acute or progressive allograft rejection.
Human leukocyte antigen eplet matching
As expected, greater degree of HLA eplet mismatch has been associated with higher sensitization. In an adult study of 66 non-sensitized (PRA < 10%) patients who had a failed first kidney transplant, immunosuppression withdrawal (discontinuation of anti-metabolite and weaning of calcineurin inhibitor), African American race, HLA-DQ eplet mismatching, and graft intolerance syndrome (allograft pain, fever or hematuria), were associated with becoming highly sensitized, defined as a PRA ! 80% [45] . Use of HLA-DR and HLA-DQ eplet matching may increase acceptable offers to pediatric patients on the waitlist, as demonstrated using HLAMatchmaker on 16 patients [46 && ]. Eplet mismatch is common at HLA-DR/DQ. There may be increased eplet matching that would not have been predicted with traditional DR/DQ matching that could place potential recipients at lower risk to develop dnDSA. A Canadian study utilizing HLAMatchmaker with 286 kidney donor-recipient pairs defined optimal thresholds for epitope mismatching for DR and DQ, and at median of 6.9 years, 0 and 2.7% of patients developed dnDSA to DR and DQ, respectively [47] . Although eplet threshold mismatch thresholds are still to be determined in pediatric populations, this is an exciting new tool to aid in kidney allocation.
CONCLUSION
These studies demonstrate that pretransplant and posttransplant histocompatibility monitoring plays a role in determining immunologic risk before, during and following kidney transplant. Degree of HLA mismatch, including HLA-DR and HLA-DQ, although excluded from the current kidney allocation system, should weigh-in on decisions for accepting donor kidneys. Posttransplant immune monitoring still poses challenges on how to interpret dnDSA data in the absence of acute rejection despite evidence linking it to poorer allograft outcomes. The choice of an appropriately matched donor kidney for a pediatric candidate has longterm consequences for kidney allograft and recipient outcomes.
